Laboratory identification of factor VIII inhibitors in the real world: The experience from Australasia

Haemophilia

Volumn 16, Issue 4, 2010, Pages 662-670

  Favaloro, E J ^a   Bonar, R ^a   Kershaw, G ^b   Mohammed, S ^a   Duncan, E ^c   Marsden, K ^d  

^a WESTMEAD HOSPITAL   (Australia)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^c Division of Haematology   (Australia)

^d ROYAL HOBART HOSPITAL   (Australia)

Author keywords

Bethesda; Factor inhibitors; Laboratory testing; Nijmegen; Proficiency testing

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR;

ANALYTIC METHOD; ANTIBODY TITER; ARTICLE; AUSTRALIA; HUMAN; LABORATORY; NEW ZEALAND; PRIORITY JOURNAL; STANDARDIZATION;

AUSTRALASIA; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION TESTS; FACTOR VIII; HUMANS; QUALITY ASSURANCE, HEALTH CARE; QUESTIONNAIRES;

EID: 77449093450     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2009.02173.x     Document Type: Article

References (14)

1. Verbruggen B. Diagnosis and quantification of factor VIII inhibitors. Haemophilia 2009, Feb 18. [Epub ahead of print]
2. Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia 2009, 15:1027-31.
3. Sahud MA, Pratt KP, Zhukov O, Qu K, Thompson AR. ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay. Haemophilia 2007, 13:317-22.
4. Kasper CK, Aledort LM, Counts RB. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975, 34:869-72.
5. Verbruggen B, Novakova I, Wessels H, Boezeman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995, 73:247-51.
6. Giles AR, Verbruggen B, Rivard GE, Teitel J, Walker I. A detailed comparison of the performance of the standard versus the Nijmegen modification of the Bethesda assay in detecting factor VIII:C inhibitors in the haemophilia A population of Canada. Thromb Haemost 1998, 79:872-5.
7. Verbruggen B, van Heerde W, Novákovà I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen Modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost 2002, 88:362-4.
8. Reber G, Aurousseau MH, Dreyfus M. Interlaboratory variability of the measurement of low titer factor VIII:C inhibitor in haemophiliacs: improvement by the Nijmegen modification of the Bethesda assay and the use of common lyophilized plasmas. Haemophilia 1999, 5:292-3.
9. Favaloro EJ, Bonar R, Duncan E. Identification of factor inhibitors by diagnostic haemostasis laboratories: a large multi-centre evaluation. Thromb Haemost 2006, 96:73-8.
10. Favaloro EJ, Bonar R, Duncan E. Mis-identification of factor inhibitors by diagnostic haemostasis laboratories: recognition of pitfalls and elucidation of strategies. A follow up to a large multicentre evaluation. Pathology 2007, 39:504-11.
11. Peerschke EI, Castellone DD, Ledford-Kraemer M, Van Cott EM, Meijer P. Laboratory assessment of factor VIII inhibitor titer: the North American Specialized Coagulation Laboratory Association experience. Am J Clin Pathol 2009, 131:552-8.
12. Kershaw G, Jayakodi D, Dunkley S. Laboratory identification of factor inhibitors: the perspective of a large tertiary hemophilia centre. Semin Thromb Hemost 2009, 35:760-8.
13. Kitchen S, Jennings I, Preston FE, Kitchen DP, Woods TAL, Walker ID. Inter-laboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK NEQAS for blood coagulation. Semin Thromb Hemost 2009, 35:778-85.
14. Meijer P, Verbruggen B. The between-laboratory variation of factor VIII inhibitor testing: the experience of the external quality assessment programme of the ECAT Foundation. Semin Thromb Hemost 2009, 35:786-93.